Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug 22;318(8):748-750.
doi: 10.1001/jama.2017.9924.

Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial

Dhruv S Kazi  1 , Joanne Penko  2 , Pamela G Coxson  2 , Andrew E Moran  3 , Daniel A Ollendorf  4 , Jeffrey A Tice  5 , Kirsten Bibbins-Domingo  5
Affiliations

Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial

Dhruv S Kazi et al. JAMA. .

Abstract

This study uses the results of the FOURIER trial to assess the current cost-effectiveness of PCSK9 inhibitors over the lifetime analytic horizon for patients with atherosclerotic cardiovascular disease in the United States.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Ollendorf reports being an employee of the Institute for Clinical and Economic Review, which is funded by grants from the Laura and John Arnold Foundation, Blue Shield of California Foundation, and the California Healthcare Foundation. The organization’s annual summit is supported by dues from Aetna, America’s Health Insurance Plans, Anthem, Blue Shield of California, CVS Caremark, Express Scripts, Harvard Pilgrim Health Care, Omeda Rx, United Healthcare, Kaiser Permanente, Premera Blue Cross, AstraZeneca, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, National Pharmaceutical Council, Takeda, Pfizer, Novartis, Eli Lilly, and Humana. Dr Tice reports receiving grant funding from the Institute for Clinical and Economic Review. No other disclosures are reported.

Comment in

References

    1. Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316(7):743-753. - PubMed
    1. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722. - PubMed
    1. National Center for Health Statistics National Health and Nutrition Examination Survey, 2005-2012. https://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm. Accessed March 28, 2017.
    1. Truven Health Analytics Red Book Online. http://truvenhealth.com/products/micromedex/product-suites/clinical-know.... Accessed April 10, 2017.
    1. Beasley D, Hummer C. Update 1—Amgen discounts cholesterol drug, but payers want more. http://www.reuters.com/article/heart-amgen-pricing-idUSL2N1GU23H. Accessed April 8, 2017.

MeSH terms